(BEAM) Beam Therapeutics - Overview
Stock: Base Editing Therapies
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 75.5% |
| Relative Tail Risk | -13.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.45 |
| Alpha | -15.92 |
| Character TTM | |
|---|---|
| Beta | 1.643 |
| Beta Downside | 1.715 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.49% |
| CAGR/Max DD | -0.24 |
Description: BEAM Beam Therapeutics January 14, 2026
Beam Therapeutics Inc. (NASDAQ: BEAM) is a Cambridge-based biotech focused on precision genetic medicines using base-editing and CRISPR-derived platforms. Its pipeline centers on in-vivo liver-targeted LNP programs (BEAM-301 for glycogen storage disease 1a, BEAM-302 for severe alpha-1 antitrypsin deficiency) and a hematology program (BEAM-101 for sickle-cell disease), with additional early-stage assets such as the anti-CD117 antibody BEAM-103, a cell-therapy candidate BEAM-104, and ex-vivo CAR-T candidates (e.g., BEAM-201).
Strategic collaborations amplify its R&D reach: a multi-year agreement with Pfizer funds in-vivo base-editing projects for rare liver, muscle, and CNS disorders; a preclinical deal with Apellis targets complement-system genes; partnerships with Verve (cardiovascular), Sana (CRISPR Cas12b for cell therapy), and Orbital Therapeutics (RNA design). These alliances collectively provide non-dilutive capital and access to complementary expertise.
Key financial metrics (Q2 2024): cash and equivalents ≈ $620 million, giving a runway of roughly 18 months at current burn; market capitalization ≈ $2.3 billion; and a recent Phase 1/2 read-out for BEAM-101 showed a ≈ 50 % reduction in hemolysis biomarkers and a favorable safety profile, positioning the program for a Phase 2/3 launch decision in 2025. The broader gene-editing sector is benefiting from expanding FDA guidance on genome-editing therapies and increasing investor appetite for high-precision, potentially curative modalities.
Given the early-stage nature of most assets and the reliance on partnership funding, valuation hinges heavily on the timing and outcomes of BEAM-101 and the liver-targeted LNP programs; a delay or adverse safety signal would materially downgrade the upside.
For a deeper quantitative assessment, see the ValueRay analysis of BEAM.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -414.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.27 > 0.02 and ΔFCF/TA -14.46 > 1.0 |
| NWC/Revenue: 1644 % < 20% (prev 222.9%; Δ 1422 % < -1%) |
| CFO/TA -0.26 > 3% & CFO -338.2m > Net Income -414.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (102.6m) vs 12m ago 24.46% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 4.49% > 50% (prev 29.85%; Δ -25.36% > 0%) |
| Interest Coverage Ratio: -19.47 > 6 (EBITDA TTM -430.1m / Interest Expense TTM 23.2m) |
Altman Z'' -8.32
| A: 0.70 (Total Current Assets 1.10b - Total Current Liabilities 182.6m) / Total Assets 1.31b |
| B: -1.44 (Retained Earnings -1.89b / Total Assets 1.31b) |
| C: -0.36 (EBIT TTM -452.2m / Avg Total Assets 1.24b) |
| D: -5.47 (Book Value of Equity -1.89b / Total Liabilities 345.1m) |
| Altman-Z'' Score: -8.32 = D |
What is the price of BEAM shares?
Over the past week, the price has changed by -9.15%, over one month by +3.91%, over three months by +15.01% and over the past year by +8.99%.
Is BEAM a buy, sell or hold?
- StrongBuy: 10
- Buy: 4
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BEAM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 47.2 | 69.3% |
| Analysts Target Price | 47.2 | 69.3% |
| ValueRay Target Price | 27.1 | -3% |
BEAM Fundamental Data Overview February 01, 2026
P/B = 2.9014
Revenue TTM = 55.7m USD
EBIT TTM = -452.2m USD
EBITDA TTM = -430.1m USD
Long Term Debt = 151.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 12.7m USD (from shortTermDebt, last quarter)
Debt = 151.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -116.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.88b USD (2.80b + Debt 151.4m - CCE 1.07b)
Interest Coverage Ratio = -19.47 (Ebit TTM -452.2m / Interest Expense TTM 23.2m)
EV/FCF = -5.33x (Enterprise Value 1.88b / FCF TTM -352.4m)
FCF Yield = -18.75% (FCF TTM -352.4m / Enterprise Value 1.88b)
FCF Margin = -632.6% (FCF TTM -352.4m / Revenue TTM 55.7m)
Net Margin = -744.4% (Net Income TTM -414.6m / Revenue TTM 55.7m)
Gross Margin = -639.3% ((Revenue TTM 55.7m - Cost of Revenue TTM 411.8m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.43 (Enterprise Value 1.88b / Total Assets 1.31b)
Interest Expense / Debt = 7.20% (Interest Expense 10.9m / Debt 151.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -357.2m (EBIT -452.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.02 (Total Current Assets 1.10b / Total Current Liabilities 182.6m)
Debt / Equity = 0.16 (Debt 151.4m / totalStockholderEquity, last quarter 966.0m)
Debt / EBITDA = 0.27 (negative EBITDA) (Net Debt -116.5m / EBITDA -430.1m)
Debt / FCF = 0.33 (negative FCF - burning cash) (Net Debt -116.5m / FCF TTM -352.4m)
Total Stockholder Equity = 967.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.41% (Net Income -414.6m / Total Assets 1.31b)
RoE = -42.86% (Net Income TTM -414.6m / Total Stockholder Equity 967.4m)
RoCE = -40.42% (EBIT -452.2m / Capital Employed (Equity 967.4m + L.T.Debt 151.4m))
RoIC = -36.93% (negative operating profit) (NOPAT -357.2m / Invested Capital 967.4m)
WACC = 11.65% (E(2.80b)/V(2.95b) * Re(11.97%) + D(151.4m)/V(2.95b) * Rd(7.20%) * (1-Tc(0.21)))
Discount Rate = 11.97% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 8.23%
Fair Price DCF = unknown (Cash Flow -352.4m)
EPS Correlation: 11.69 | EPS CAGR: 28.07% | SUE: 1.06 | # QB: 1
Revenue Correlation: -32.24 | Revenue CAGR: -35.79% | SUE: -0.03 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.16 | Chg30d=-0.005 | Revisions Net=+1 | Analysts=7
EPS next Year (2026-12-31): EPS=-4.60 | Chg30d=-0.045 | Revisions Net=-2 | Growth EPS=-9.0% | Growth Revenue=+15.4%